Assessing the impact of Lp(a) lowering with pelacarsen (YQJ330) on major cardiovascular events in patients with CVD (Lp(a)HORIZON) (NCT04023552)

Educational Partners and Supporters

Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum. (Founding Partner)